SCA
KERX

SAC Capital Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

SAC Capital Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,525,058
Closed -$26M – 1325
2014
Q1 		$26M Buy
+1,525,058
New +$23M 0.13% 210

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

SAC Capital Advisors's KERX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 1,525,058 shares — an estimated $26M sold.

SAC Capital Advisors first reported a position in KERX in Q1 2014 and held it in 1 quarter. The position peaked at $26M in Q1 2014. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 1,525,058 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $26M.
  • SAC Capital Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Keryx Biopharmaceuticals Inc position peaked at $26M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.